Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30215% above fair value
$333.25+1.09 (+0.33%)
Close on Nov 18, 2026Market cap $15.91BP/E –Yield –
Charles River Laboratories International revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Charles River Laboratories International's revenue for the twelve months ending Jun 27, 2026 was $4.00B, down 0.7% year over year. For fiscal 2025 it was $4.02B, down 0.9% from the year before. Over ten years it grew 11.4% a year on average. The highest annual figure on record is $4.13B in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $4.02B | -0.9% |
| FY2024 | Dec 28, 2024 | $4.05B | -1.9% |
| FY2023 | Dec 30, 2023 | $4.13B | +3.9% |
| FY2022 | Dec 31, 2022 | $3.98B | +12.3% |
| FY2021 | Dec 25, 2021 | $3.54B | +21.1% |
| FY2020 | Dec 26, 2020 | $2.92B | +11.5% |
| FY2019 | Dec 28, 2019 | $2.62B | +15.7% |
| FY2018 | Dec 29, 2018 | $2.27B | +22.0% |
| FY2017 | Dec 30, 2017 | $1.86B | +10.5% |
| FY2016 | Dec 31, 2016 | $1.68B | +23.3% |
| FY2015 | Dec 26, 2015 | $1.36B | +5.1% |
| FY2014 | Dec 27, 2014 | $1.30B | +11.3% |
| FY2013 | Dec 28, 2013 | $1.17B | +3.2% |
| FY2012 | Dec 29, 2012 | $1.13B | -1.1% |
| FY2011 | Dec 31, 2011 | $1.14B | +0.8% |
| FY2010 | Dec 25, 2010 | $1.13B | -3.3% |
| FY2009 | Dec 26, 2009 | $1.17B | -9.5% |
| FY2008 | Dec 27, 2008 | $1.30B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $1.00B | -2.7% |
| Q1 FY2026 | Mar 28, 2026 | $995.83M | +1.2% |
| Q4 FY2025 | Dec 27, 2025 | $994.23M | -0.8% |
| Q3 FY2025 | Sep 27, 2025 | $1.00B | -0.5% |
| Q2 FY2025 | Jun 28, 2025 | $1.03B | +0.6% |
| Q1 FY2025 | Mar 29, 2025 | $984.17M | -2.7% |
| Q4 FY2024 | Dec 28, 2024 | $1.00B | -1.1% |
| Q3 FY2024 | Sep 28, 2024 | $1.01B | -1.6% |
| Q2 FY2024 | Jun 29, 2024 | $1.03B | -3.2% |
| Q1 FY2024 | Mar 30, 2024 | $1.01B | -1.7% |
| Q4 FY2023 | Dec 30, 2023 | $1.01B | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.03B | +3.8% |
| Q2 FY2023 | Jul 1, 2023 | $1.06B | +8.9% |
| Q1 FY2023 | Apr 1, 2023 | $1.03B | +12.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.10B | +21.5% |
| Q3 FY2022 | Sep 24, 2022 | $989.16M | +10.4% |
| Q2 FY2022 | Jun 25, 2022 | $973.13M | +6.4% |
| Q1 FY2022 | Mar 26, 2022 | $913.93M | +10.8% |
| Q4 FY2021 | Dec 25, 2021 | $905.05M | +14.4% |
| Q3 FY2021 | Sep 25, 2021 | $895.94M | +20.5% |
| Q2 FY2021 | Jun 26, 2021 | $914.61M | +34.0% |
| Q1 FY2021 | Mar 27, 2021 | $824.57M | +16.6% |
| Q4 FY2020 | Dec 26, 2020 | $790.99M | +14.4% |
| Q3 FY2020 | Sep 26, 2020 | $743.30M | +11.3% |
| Q2 FY2020 | Jun 27, 2020 | $682.58M | +3.8% |
| Q1 FY2020 | Mar 28, 2020 | $707.06M | +17.0% |
| Q4 FY2019 | Dec 28, 2019 | $691.14M | +14.9% |
| Q3 FY2019 | Sep 28, 2019 | $667.95M | +14.1% |
| Q2 FY2019 | Jun 29, 2019 | $657.57M | +12.3% |
| Q1 FY2019 | Mar 30, 2019 | $604.57M | +22.4% |
| Q4 FY2018 | Dec 29, 2018 | $601.53M | +25.7% |
| Q3 FY2018 | Sep 29, 2018 | $585.30M | +26.1% |
| Q2 FY2018 | Jun 30, 2018 | $585.30M | +24.8% |
| Q1 FY2018 | Mar 31, 2018 | $493.97M | +10.8% |
| Q4 FY2017 | Dec 30, 2017 | $478.48M | +2.5% |
| Q3 FY2017 | Sep 30, 2017 | $464.23M | +9.0% |
| Q2 FY2017 | Jul 1, 2017 | $469.13M | – |
| Q1 FY2017 | Apr 1, 2017 | $445.76M | – |
| Q4 FY2016 | Dec 31, 2016 | $466.79M | – |
| Q3 FY2016 | Sep 24, 2016 | $425.72M | – |
See a number that looks wrong?